HLN Haleon plc
USHealthcareAs of 2026-07-10 16:00
Why HLN matters now
Haleon plc (HLN) is a US stock in Healthcare. The latest InvestLog snapshot shows $9.76 with +0.51% on the session and $42.98B in market capitalization; recent performance reads 1-month -2.61% and YTD -11.37%.
The latest financial table shown here is Q4 2025, with revenue of $5.52B, net income of $855.7M, and EPS of $0.19. Investors can compare that operating picture with valuation signals such as P/E 31.80 and FCF yield 3.2%.
The latest indexable market news headline is "LCUT vs. HLN: Which Stock Is the Better Value Option?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $10.20. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
31.80
PEG
0.40
P/B
1.84
P/S
3.58
EV/EBITDA
17.73
DCF Value
$20.55
FCF Yield
3.2%
Div Yield
2.1%
Margins & Returns
Gross Margin
61.5%
Operating Margin
18.8%
Net Margin
12.6%
ROE
6.4%
ROA
3.2%
ROIC
4.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $5.52B | $855.7M | $0.19 |
| FY 2025 | $10.79B | $1.63B | $0.36 |
| Q2 2025 | $5.48B | $806.0M | $0.18 |
| Q1 2025 | $2.74B | $403.0M | $0.09 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$10.20
Target (Median)
$10.20
Target Range
$10.20 - $10.20
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
GB
Exchange
—
Beta
0.25
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.